Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 3/20 | 0.49 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.42 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 5/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1753627 | 0.83 | EPHX2 (0.53) | EPHX2DPP8DPP7MEN1ALDH1A1 | |
| SCHEMBL17540490 | 0.81 | MEN1 (0.43) | EPHX2DPP8DPP7MEN1ALDH1A1 | |
| SCHEMBL15247214 | 0.81 | MEN1 (0.43) | EPHX2DPP8DPP7MEN1ALDH1A1 | |
| SCHEMBL22874689 | 0.81 | MEN1 (0.43) | EPHX2DPP8DPP7MEN1ALDH1A1 | |
| SCHEMBL19981983 | 0.81 | DPP7 (0.53) | EPHX2DPP8DPP7DPP4DPP9 | |
| SCHEMBL22875287 | 0.80 | EPHX2 (0.50) | EPHX2DPP8DPP7MEN1ALDH1A1 | |
| SCHEMBL22875196 | 0.80 | EPHX2 (0.70) | EPHX2DPP8DPP7MEN1ALDH1A1 | |
| SCHEMBL17546275 | 0.79 | ALDH1A1 (0.63) | MEN1ALDH1A1KMT2A | |
| SCHEMBL13901222 | 0.78 | EPHX2 (0.51) | EPHX2DPP8DPP7MEN1ALDH1A1 | |
| SCHEMBL16095218 | 0.78 | EPHX2 (0.48) | EPHX2DPP8DPP7MEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11753397-B2 | Cereblon binders for the degradation of ikaros | C4 THERAPEUTICS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-20210009559-A1 | CEREBLON BINDERS FOR THE DEGRADATION OF IKAROS | C4 THERAPEUTICS, INC. (US) | 2021-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11753397-B2 | Cereblon binders for the degradation of ikaros | CRBN, IKZF1, IKZF3 | EPHX2 4282/4885DPP8 4547/4885DPP7 4122/4885 |
| US-20210009559-A1 | CEREBLON BINDERS FOR THE DEGRADATION OF IKAROS | CRBN, IKZF1, IKZF3 | EPHX2 4118/4885DPP8 3864/4885DPP7 3627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.